ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1763

Time to Diagnosis of ANCA-Associated Vasculitides : Data from French Vasculitis Study Group Registry

Caroline Morbieu, Maher Banjari, Benjamin Terrier, Pascal Cohen, Claire Le Jeunne, Luc Mouthon, Xavier Puéchal and Loïc Guillevin for the French Vasculitis Study Group, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: ANCA, diagnosis and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Vasculitis Poster II: ANCA-Associated Vasculitis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Diagnosing ANCA-associated vasculitides (AAVs) can be challenging. Their clinical presentations are numerous and the time to diagnosis may range from days to years.1,2 The impact of delayed diagnosis on AAV outcome has not been established. This study was conducted to assess the first-symptom-to-diagnosis times for patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).

Methods:

Adults diagnosed with new onset GPA or MPA between 2005 and 2015 and followed at Cochin National Referral Center for Vasculitides were selected from the French Vasculitis Study Group (FVSG) Registry. Patients were excluded when the date and first symptom were incomplete. First symptom (systemic vs ENT), clinical and laboratory findings, Birmingham Vasculitis Activity Score (BVAS) at diagnosis, time to diagnosis and Vasculitis Damage Index (VDI) at last visit were collected from the FVSG registry’s database and medical records. The first symptom had been systematically assessed by the treating physician at diagnosis. Data are expressed as median, interquartile range. Pearson and Mann–Whitney tests were used to analyze data.

Results:

Among 257 patients screened, 29 were excluded. The study population comprised 228 patients: 169 with GPA and 59 with MPA (median age at diagnosis 55 years [42–65]; M/F sex ratio 0.81). At diagnosis, their median BVAS was 12 [7–18], 44% had renal involvement and 22% had 2009 Five Factor Scores ≥1. The median time to diagnosis was 5.1 [2.1–16.2] (range 0.1–356) months, for which GPA and MPA did not differ significantly. Among AAV patients’ first symptoms, 174 (76%) were systemic and 54 (24%) were ENT, with longer times to diagnosis when ENT was the first symptom (8.65 vs 4.1 systemic; P<0.0001). The median time from first ENT to first systemic symptom was 6.1 [3.6–33] months. The time to diagnosis was significantly longer in women (6.1 vs 4.1 men; P<0.05) and in the absence of renal involvement (6.1 vs 3.2 renal involvement; P<0.01). No association was found between time to diagnosis and age, date of diagnosis, BVAS at diagnosis, or VDI at last visit. Thirty-nine (17%) patients, mostly with GPA (27, 69%), were diagnosed >24 months after the first symptom, which was mainly arthritis/arthralgias (n=9), retroorbital tumor (n=5), purpura/livedo (n=5), thoracic nodules (n=5), ENT (n=5) or others (n=10). Corticosteroids (4 patients) or immunosuppressants (3 patients) were prescribed before AAV diagnosis.

Conclusion:

The time to AAV diagnosis remains long, especially when the first symptom involves ENT. ANCA testing might shorten the time to diagnosis, and should be considered even in pauci-symptomatic patients.

References:

1 Yacyshyn E. Joint Bone Spine 2016;83:599.

2 Mohammad AJ. Rheumatology (Oxford) 2007;46:1329.


Disclosure: C. Morbieu, None; M. Banjari, None; B. Terrier, None; P. Cohen, None; C. Le Jeunne, None; L. Mouthon, None; X. Puéchal, None; L. Guillevin for the French Vasculitis Study Group, None.

To cite this abstract in AMA style:

Morbieu C, Banjari M, Terrier B, Cohen P, Le Jeunne C, Mouthon L, Puéchal X, Guillevin for the French Vasculitis Study Group L. Time to Diagnosis of ANCA-Associated Vasculitides : Data from French Vasculitis Study Group Registry [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/time-to-diagnosis-of-anca-associated-vasculitides-data-from-french-vasculitis-study-group-registry/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/time-to-diagnosis-of-anca-associated-vasculitides-data-from-french-vasculitis-study-group-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology